Burns

Each year, approximately 200,000 patients in the U.S. receive care in burn centers, with around 40,000 requiring hospitalization due to the severity of their burns. For those with catastrophic, full-thickness burns covering over 30% of the body surface, extensive grafting is typically necessary, and products like Regenicin’s cultured skin substitute, NovaDerm® aim to improve outcomes by minimizing the amount of harvested skin needed for autografts (grafts from the patient’s own skin). This reduces donor site trauma, the number of required surgeries, hospitalization days, scarring, infection risk, and healing time. Cultured skin substitute technology has shown potential in clinical trials, especially in pediatric cases with burns covering 50% to over 90% of body surface area, where traditional skin grafting would be particularly grueling.